Results 121 to 130 of about 16,194 (165)
Some of the next articles are maybe not open access.
Chronic Hepatitis C and Direct Acting Antivirals
Surgical Pathology Clinics, 2018The hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is the most common cause of end-stage liver disease requiring liver transplant. Over the last 10 years, direct acting antiviral therapies have revolutionized HCV treatment, increasing the cure rates from less than 50% to more than 90% in those who reach access
Maria, Westerhoff, Joseph, Ahn
openaire +2 more sources
Resistance to Direct-Acting Antivirals
Current Hepatitis Reports, 2012Viral resistance corresponds to the selection, during treatment, of pre-existing viral variants less susceptible to the drug’s inhibitory activity because they bear amino acid substitutions altering the drug target. Hepatitis C virus (HCV) drugs in development can be split into two groups according to their barrier to resistance.
openaire +1 more source
Resistance to direct-acting antiviral agents
Current Opinion in HIV and AIDS, 2015This article examines the dynamics and factors underlying hepatitis C virus (HCV) resistance, along with their impact on daily clinical management of HCV-infected patients.Across available treatment-regimens, GT-3 is the most difficult-to-cure genotype, but also genotype-1a may show lower success-rates compared with genotype-1b.
Valeria, Cento +2 more
openaire +2 more sources
Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma
Surgical Oncology Clinics of North AmericaTherapy for chronic hepatitis C virus infection with direct-acting antiviral agents (DAAs) has been highly successful in achieving sustained virological response (SVR) with associated improvements in liver dysfunction, liver-related mortality, and transplant-free survival.
Ifrah, Fatima +2 more
openaire +2 more sources
Direct-acting antiviral treatment for patients with hepatocellular carcinoma
Current Opinion in Gastroenterology, 2018Hepatocellular carcinoma (HCC) affects a significant portion of patients with hepatitis C. The use of direct-acting antiviral (DAA) agents has transformed the disease outcomes in this patient group.Hepatitis C virus (HCV) response to DAAs can be affected by the presence of HCC, whereas DAA therapy may affect the risk of HCC recurrence in patients with ...
Tatyana, Kushner +2 more
openaire +2 more sources
Interferon free therapy with direct acting antivirals for HCV
Liver International, 2013AbstractThe current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG‐IFN) plus ribavirin (RBV) regimen.
Tarik, Asselah, Patrick, Marcellin
openaire +2 more sources
Direct acting antivirals failure: cause and retreatment options
Expert Review of Gastroenterology & Hepatology, 2018Chronic hepatitis C (HCV) infection is a systemic life-threatening condition that can lead to hepatic and extra-hepatic complications. Sustained virological response (SVR) is associated with a regression of most liver and non-liver manifestations, which reduce mortality.
Lucia, Parlati, Stanislas, Pol
openaire +2 more sources
Extrahepatic manifestations of HCV: the role of direct acting antivirals
Expert Review of Anti-infective Therapy, 2017Hepatitis C virus (HCV) represents a major health concern, as nearly 3 million people become newly infected by this pathogen annually. The majority of infected individuals fail to clear the virus, and chronicity is established. Chronic HCV patients are at high risk for liver disease, ranging from mild fibrosis to cirrhosis and severe hepatocellular ...
María Laura, Polo, Natalia, Laufer
openaire +2 more sources
Role of Liver Biopsy in the Era of Direct-Acting Antivirals
Current Gastroenterology Reports, 2013An accurate assessment of the degree of fibrosis or presence of cirrhosis is critical both for the appropriate management of, and to provide prognosis for, patients with chronic hepatitis C infection. In the new era of direct acting antivirals, large numbers of patients may enter therapy, and although liver biopsy remains the gold standard, it is not ...
Humberto C, Gonzalez +2 more
openaire +2 more sources
[Direct-acting antiviral-resistant variant].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, IFN-free NS5A inhibitor daclatasvir and protease inhibitor asunaprevir combination treatment was approved for genotype 1b HCV-infected patients who were ineligible or who failed to respond to previous therapies. NS5A inhibitor-resistant variants occasionally exist in HCV-infected patients who have never been exposed to direct-acting ...
Michio, Imamura, Kazuaki, Chayama
openaire +1 more source